Biocon Stays The Course For Neulasta, Herceptin Biosimilars
Executive Summary
Biocon reported robust first-quarter numbers and remains upbeat on the prospects of taking its biosimilars including pegfilgrastim and trastuzumab to Europe and the US notwithstanding regulatory setbacks faced by some seasoned competitors recently.